PHASE I STUDY OF BMS188667 IN PSORIASIS VULGARIS

这项研究是一项多中心、开放标签剂量递增I期试验 旨在评估安全性、药代动力学和初步活性 BMS-188667四次静脉注射在患者中的应用 患有牛皮癣。BMS-188667(CTLA4Ig)代表了一种新的药剂类别 它的目标是阻断T细胞激活的第二个信号。 越来越多的证据表明，T细胞在人类免疫系统中起着关键作用。 银屑病的发病机制。这种药物有可能提供另一种 严重疾病患者的治疗选择。审判可能会 也有助于阐明参与的免疫学机制 银屑病的发病机制。

This study is a multi-center, open-label dose escalation Phase I trial designed to assess the safety, pharmacokinetics and preliminary activity of BMS-188667 administered as four intravenous injections in patients with psoriasis. BMs-188667 (CTLA4Ig) represents a new class of agent that targets the blockade of the second signal in T cell activation. There is increasing evidence that the T cell is pivotal in the pathogenesis of psoriasis. The drug has the potential to provide another treatment alternative for patients with severe disease. The trial may also help elucidate the immunologic mechanisms involved in the pathogenesis of psoriasis.